S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer
Status:
Terminated
Trial end date:
2019-12-31
Target enrollment:
Participant gender:
Summary
This randomized Phase III trial studies how well the combination of fulvestrant and
everolimus together or the combination of anastrozole, fulvestrant and everolimus together,
improve progression-free survival (PFS) versus fulvestrant alone.